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Abstract
Changes in the intracellular calcium concentration govern cytoskeletal rearrangement, mitosis, apoptosis,
transcriptional regulation or synaptic transmission, thereby, regulating cellular effector and organ functions. Calcium
binding proteins respond to changes in the intracellular calcium concentration with structural changes, triggering
enzymatic activation and association with downstream proteins. One type of calcium binding proteins are EF-hand
super family proteins. Here, we describe two recently discovered homologous EF-hand containing adaptor proteins,
Swiprosin-1/EF-hand domain containing 2 (EFhd2) and Swiprosin-2/EF-hand domain containing 1 (EFhd1), which
are related to allograft inflammatory factor-1 (AIF-1). For reasons of simplicity and concision we propose to name
Swiprosin-1/EFhd2 and Swiprosin-2/EFhd1 from now on EFhd2 and EFhd1, according to their respective gene
symbols. AIF-1 and Swiprosin-1/EFhd2 are already present in Bilateria, for instance in Drosophila melanogaster and
Caenhorhabditis elegans. Swiprosin-2/EFhd1 arose later from gene duplication in the tetrapodal lineage. Secondary
structure prediction of AIF-1 reveals disordered regions and one functional EF-hand. Swiprosin-1/EFhd2 and
Swiprosin-2/EFhd1 exhibit a disordered region at the N-terminus, followed by two EF-hands and a coiled-coil
domain. Whereas both proteins are similar in their predicted overall structure they differ in a non-homologous
stretch of 60 amino acids just in front of the EF-hands. AIF-1 controls calcium-dependent cytoskeletal
rearrangement in innate immune cells by means of its functional EF-hand. We propose that Swiprosin-1/EFhd2 as
well is a cytoskeleton associated adaptor protein involved in immune and brain cell function. Pro-inflammatory
conditions are likely to modulate expression and function of Swiprosin-1/EFhd2. Swiprosin-2/EFhd1, on the other
hand, modulates apoptosis and differentiation of neuronal and muscle precursor cells, probably through an
association with mitochondria. We suggest furthermore that Swiprosin-2/EFhd1 is part of a cellular response to




2+) regulate enzyme activities, cytoske-
letal and transcriptional regulation, mitosis or apoptosis,
gene expression, synaptic communication and homeos-
tasis of reactive oxygen species (ROS) [1]. Changes in
the intracellular Ca
2+ concentration therefore control
cellular effector as well as organ functions, such as
immune cell activation or brain function, to name only
af e w .C a
2+ signaling is a consequence of temporary
and/or local increases in the intracellular Ca
2+ concen-
tration, through the opening of Ca
2+ channels in the
endoplasmic reticulum (ER) and the plasma membrane.
Ca
2+ acts as a ubiquitous, diffusible second messenger
that is stored in the ER and mitochondria. It diffuses
from the ER into the cytoplasm due to opening of Ca
2+
channels in the ER membrane in response to increases
in inositol-1,4,5-trisphosphate (IP3), a metabolite of
the cleavage of phosphatidylinositol-4,5-bisphosphate
(PIP2) by members of the PI-phospholipase C family of
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any medium, provided the original work is properly cited.enzymes. A wide variety of cell surface receptors includ-
ing growth factor receptors, cytokine receptors, G-
protein coupled receptors (GPCR), integrins, the high
affinity receptor for immunoglobulin E (IgE) - FcεR1 -
on mast cells as well as B and T cell receptors (BCR
and TCR) can activate phospholipase C enzymes directly
and indirectly through different mechanisms [2]. The
depletion of intracellular Ca
2+ stores and the concomi-
tant rise in the cytosolic Ca
2+ concentration induces
influx of extracellular Ca
2+ across the plasma membrane
through store operated calcium entry (SOCE) and cal-
cium release activated calcium (CRAC) channels. Key
players in this process are stromal interaction mole-
cules 1 and 2 (STIM1 and 2), which sense the deple-
tion of ER Ca
2+ stores, and ORAI1, which represents a
pore subunit of the CRAC channel (for review see
references [3,4]).
Ca
2+-binding proteins of the EF-hand super family
[5-7] are involved in all of the above-mentioned cellular
processes. EF-hand bearing proteins are heterogeneous
in their structures and calcium binding properties. R. H.
Kretsinger, who discovered a Ca
2+-binding helix-loop-
helix motif in the structure of Parvalbumin [8], named
this motif “EF-hand”. The corresponding linear sequence
motif (Pfam PF00036; http://pfam.sanger.ac.uk/) has
thereafter been discovered in the amino acid sequences
of many other calcium-binding proteins [9-13]. Here, we
provide information about the recently described
EF-hand proteins Swiprosin-1/EFhd2 and Swiprosin-
2/EFhd1, which are related to another EF-hand protein,
allograft inflammatory factor-1 (AIF-1; also: Iba1,
ionized calcium binding adapter molecule 1). Although
our own work focuses on B cell development and signal-
ing we provide information for a broader readership
here. There are many synonyms for Swiprosin/EFhd
genes, transcripts and proteins (Additional file 1, Table S1).
Whereas the nomenclature of the genes is unambiguous,
alternative names complicate work with the proteins
(Additional file 1, Table S1). For simplicity and concision,
we propose to name the proteins from now on EFhd1
and EFhd2, according to their respective gene symbols.
Hence, we will refer in this review and future publications
to Swiprosin-1/EFhd2 as EFhd2 and to Swiprosin-2/EFhd1
as EFhd1.
EFhd2 and EFhd1 exhibit similar predicted secondary
structures (http://elm.eu.org) (Figure 1a), with disor-
dered regions at the N-terminus, predicted and func-
tional SH3-domain binding sites [14], followed by two
EF-hands and a coiled-coil domain at the C-terminus.
Both proteins bind indeed Ca
2+ [15,16] and exhibit a
high degree of sequence identity at the protein level
(64.58%) (Figure 1b). The only significantly different
region are amino acids (aa) 20-80 (referring to the num-
bering of EFhd2). A part of this region (aa 70-78) has
been shown by us to be important for targeting EFhd2
to detergent resistant membranes (DRM) in the murine
B cell line WEHI231 [14]. Both EFhd2 [14] and EFhd1
(Additional file 2, Figure S1) are conserved amongst
species, with an orthologue of EFhd2 in Drosophila
melanogaster (CG10641). Interestingly, regarding EFhd2
and EFhd1 from the same species (Figure 1a), or either
EFhd2 [14] and EFhd1 (Additional file 2, Figure S1)
from different species, aa 20-80 differ the most. Since
EFhd2 and EFhd1 are so similar in their other domains,
this part of the proteins is likely to specify distinct func-
tions of EFhd2 and EFhd1. One would therefore assume
that EFhd2 and EFhd1 bind proteins redundantly as well
as uniquely. When expressed in the same cellular con-
text, EFhd2 and EFhd1 might transmit Ca
2+ signals into
a different signaling outcome, especially because there is
so far no evidence for an interaction of EFhd2 with
EFhd1 (D.M. et al., unpublished data).
Evolution of the genes encoding AIF-1 (aif1),
EFhd2 (efhd2) and EFhd1 (efhd1)
The first efhd/aif1 precursor gene is present in an
ancestral species of the animal taxon Bilateria (Figure 2;
http://www.treefam.org/cgi-bin). This ancient gene
u n d e r w e n td u p l i c a t i o ni na nu n k n o w ns p e c i e s ,g i v i n g
rise to two branches. One branch represents efhd and
aif1, both of which gene products exhibit EF-hand
domains (one in AIF-1 and two in EFhd). The other
branch represents a gene encoding a unique protein in
C. elegans (WP:CE38519) (Figure 2, bottom) that con-
sists only of a coiled-coil domain at the C-terminus
(not shown). The efhd gene products contain a disor-
dered region, two central EF-hands and a C-terminal
coiled-coil domain whereas AIF-1 contains only a dis-
ordered region and two EF-hands, the second of which
is degenerate. Accordingly, the homology between aif1
and efhd genes is restricted to the region encoding the
EF-hand domains (representative result for murine
EFhd2 is shown in Additional file 3, Figure S2). This
suggests that calcium binding is the most prominent
feature of this protein family. The aif1/efhd precursor
underwent a second duplication, resulting in aif1 genes
and the efhd2 precursor. The efhd2 gene is already
present in insects where it represents the only efhd
g e n e( F i g u r e2 ) .I no n es p e c i e so ft h et a x o nEuteleos-
tomi, after the onset of Chordata development, the
ancient efhd2 gene was duplicated once more, now
representing two genes, efhd2 and efhd1,e n c o d i n gf o r
the proteins EFhd2 and EFhd1. These are - amongst
other species - present in man, mouse, rat, chicken,
zebrafish and frog. In the tetrapodal lineage, putatively
during or before development of Xenopus spec., there
was yet another duplication of the efhd2 gene. Thus,
Xenopus tropicalis contains three efhd genes, efhd1,
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proper name (ensxett00000029488_xentr). Interestingly,
t h eg e n ep r o d u c to fensxett00000029488_xentr con-
tains no EF-hands, but only disordered regions and a
coiled-coil domain. This protein might therefore com-
pete with the EF-hand containing Xenopus EFhd2 and
EFhd1 for calcium-independent binding partners. In
summary, EFhd2 is the ancestral protein, being present
for instance in worms and insects, and EFhd2 and
EFhd1 co-exist from the euteleostomic lineage on, for
instance in zebrafish, frog and later evolutionary stages.
This provokes the question as to whether the gene
duplication resulting in the efhd1 gene provided an
evolutionary advantage.
Chromosomal location of the human and murine
genes efhd2 and efhd1
The murine efhd2 gene is located on chromosome 4
(see http://www.ensembl.org for further details). It
contains 4 exons with a long intron between exon 1 and
2( 1 5k b )a n dal o n g3 ’-UTR in exon 4 (approx. 1.6 kb).
This structure is conserved in humans where the efhd2
gene is located on chromosome 1. The murine efhd2
gene is located centrally in a susceptibility locus for SLE
(Systemic Lupus Erythematodes) (LMB-1, close to
D4Mit33) on chromosome 4 [17]. The human efhd2
gene lies in the PARK7 locus (1p36.33 - 1p36.12) that is
associated with autosomal recessive early onset Parkin-
son’s disease [18]. For the human efhd2 gene product,
EFhd2, three protein-coding splice variants have been
predicted, translating into putative protein products of
177 to 240 aa. The murine efhd1 gene is localized on
chromosome 1. It is also comprised of 4 exons with an
even longer intron between exons 1 and 2 (approx. 25
kb), similar to human efhd1 (chromosome 2). For the
human efhd1 gene product, EFhd1, five protein-coding
splice variants are predicted, resulting in potential
protein products of 81 to 239 aa.
Figure 1 Predicted secondary structures and sequence comparisons of EFhd2 and EFhd1. a) Predicted secondary structures of murine
EFhd1 and EFhd2 (240 aa) (http://elm.eu.org). PR: proline-rich elements (potential SH3 domain-binding sites), EF: EF-hands, CC: coiled-coil
domain, D: disordered region. b) Aligment of murine EFhd1 (Q9D4J1) and EFhd2 (Q9D8Y0) sequences using ClustalW2 (http://www.ebi.
ac.uk/clustalw). Amino acid (aa) positions are marked on the right. “*”, identical aa, “:”, conserved aa, “.” semi conserved aa.
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Expression of EFhd2
An enhancer trap screen has identified a Drosophila
strain with an intriguing expression pattern in muscle
cells and somatic muscle precursor cells. The insertion is
in the Drosophila efhd homologue, CG10641 [19]. Fur-
long et al. [20] revealed expression of CG10641 by micro-
array analyses and in situ hybridization during mesoderm
development. Estrada et al. show expression of CG10641
in the visceral and somatic mesoderm, stage 9 ventral
head mesoderm, stage 10 head mesoderm and in hemo-
cytes but did not follow up the expression patter of
CG10641 during mesoderm differentiation [21]. However,
based on these expression data Kiefer et al. [22] propose
a function for all Drosophila CG10641-related genes in
muscle. Indeed, Renate Renkawitz-Pohl’sg r o u p( C .H o r n -
bruch and R. Renkawitz-Pohl, personal communication)
shows expression of Drosophila EFhd (CG10641 encoded)
in hematocytes and during myoblast fusion. The EFhd2
orthologue in C. elegans is expressed in pharynx, body
wall muscle, the nervous system and the ventral nerve
cord. In zebrafish the associated ESTs are expressed in
brain, eye, genitourinary tissue, gills, muscle, and olfac-
tory rosettes. In C. elegans, zebrafish and mouse the
respective orthologues may have additional functions,
including a role in the nervous system [22]. The latter
appears to be true in human and mouse, at least under
pathological conditions such as neurodegeneration, schi-
zophrenia and alcohol addiction [15,23-25].
M u s c l ei sd e r i v e df r o mm e s o d e r mb u tt h em e s o d e r m
gives also rise for instance to bone (osteoblasts and osteo-
clasts), connective tissue and hematopoietic cells. In
humans, EFhd2 becomes transiently up-regulated during
osteoblast differentiation from human mesenchymal stem
cells [26]. EFhd2 is also up-regulated during differentia-
t i o no ft h em u r i n eR A W 2 6 4m a c r o p h a g ec e l ll i n ei n t o
osteoclasts after treatment with RANK-L (receptor activa-
tor of NF-B ligand) [27]. Other cell types of mesodermal
origin expressing EFhd2 are particularly immune cells:
EFhd2 is expressed in human and primary murine mast
cells [[28,29]; our unpublished data], human and murine
B cells [30-32], in CD4
+ and CD8
+ T cells [32-34], nat-
ural killer cells (NK cells) [35] and human peripheral
blood mononuclear cells (PBMC) [36,37]. PBMC are a
heterogeneous cell population of lymphocytes (~75%
CD4
+ and CD8
+ T cells and ~25% NK and B cells),
monocytes and macrophages. In accordance, murine
efhd2 mRNA is present at relatively high abundance in
total spleen by Northern Blot, at similar levels in liver
a n dl u n g ,a n da tr e l a t i v e l yl o wa m o u n t si nk i d n e y[ 3 1 ] .
The highest expression of efhd2 has, however, been
detected in ectodermal tissue, namely brain [31]. Like-
wise, the murine EFhd2 protein was identified in mouse
brain [38], specifically in brain stem, cerebellum,
Figure 2 Phylogeny of EFhd genes. A phylogenetic tree with equal distances between different taxons was generated using efhd1 as search
parameter (http://www.treefam.org/cgi-bin). Search parameters were: accession number TF320736 / clean / equal distance / show taxa / none /
exp / selected species. Only representative species are shown for convenience. On the right hand side the employed transcript sequences are
shown. Chick, chicken (Gallus gallus), Brare, zebrafish (Danio rerio), Xentr, frog (Xenopus tropicalis), Cioin, Hydra (Ciona intestinalis), Drome, fruitfly
(Drosophila melanogaster), Caeel, worm (Caenorhabtidis elegans).
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in the hippocampus [15,23]. With the exception of
microglia cells [39] it remains to be established which
cell type(s) in the brain express EFhd2. Other cells of
ectodermal origin expressing EFhd2 are primary immor-
talized human keratinocytes [40]. Finally, during mouse
development EFhd2 is detected strongly in ectodermal
tissue such as the most rostral foregut and the caudal
hindgut at E8.5 [41]. In addition, EFhd2 is also down-
regulated in embryos deficient for the transcription factor
Foxa2 and is a marker of definitive endoderm [41]. Inter-
estingly, EFhd2 is already present in murine embryonic
stem cells (our unpublished data). Cell lines expressing
EFhd2 are all murine B cell lines we analyzed (our
unpublished data), HeLa cells [42] and NIH3T3 cells (our
u n p u b l i s h e dd a t a ) .I ns u m m a r y ,i nw o r m ,z e b r a f i s ha n d
higher vertebrates EFhd2 is not only expressed during
mesoderm development but also in endodermal and ecto-
dermal tissues. Whether this is also the case in D. mela-
nogaster remains to be determined.
Involvement of EFhd2 in immune cell activation
Innate immune cells respondt op a t h o g e na s s o c i a t e d
molecular patterns (PAMP) and to danger signals
released by necrotic cells. Many signaling elements that
are important in adaptive immunity have recently also
been shown to control innate immunity [43]. Interest-
ingly, signaling molecules of innate immune cells in
higher organisms are shared even in Drosophila where
they control for instance removal of necrotic tissue [43].
Although insects do not possess an adaptive immune
system and rely solely on their innate immune system,
they utilize ITAMs (immunoreceptor tyrosine based
activation motifs). The ITAM is a tyrosine phosphoryla-
tion consensus motif (YxxLx(7-12)Y x x L )[ 4 4 ]f o u n di n
many receptors and co-receptors of the adaptive and
innate immune system as well as in ERM (ezrin, radixin,
moesin) proteins [43]. When phosphorylated on their
tyrosine residues by Src kinases or Syk (splenic tyrosine
kinase) [45], ITAMs bind the SH2 domains of Syk,
relieving Syk from autoinhibition and eventually activat-
ing it, resulting in a positive feedback loop [45]. Syk is
key to signaling from adaptive as well as many innate
immune receptors [43,46]. We have recently shown that
murine EFhd2 is a positive regulator of Syk activity in
response to BCR stimulation in the murine B cell line
WEHI231 [14].
Hemocytes of insects are crucial players of immune
surveillance by migrating through the body, phagocyting
invading pathogens and secreting antimicrobial peptides
[47]. One type of hemocytes are the plasmatocytes
which resemble mammalian monocytic and macrophage
cells [47]. Differentiated macrophage-like hemocytes
of Drosophila express the Drosophila EFhd protein
(C. Hornbruch and R. Renkawitz-Pohl, personal com-
munication). This fits to other reports revealing Droso-
phila EFhd expression in hemocytes [48] and in the
Drosophila S2 cell line which exhibits phagocytotic
activity [47]. Many of the hematopoietic factors have
been conserved across taxonomic groups [43]. Likewise,
EFhd2 is expressed in the murine monocyte cell line
RAW264 [27], in human PBMC [36], in microglia cells
[39] and in NK-like cells [35]. EFhd2 becomes up-
regulated - together with actin - in response to stimula-
tion of the human monocyte cell line THP-1 with a
recombinant Mycobacterium bovis strain [49]. This
stimulation improved the antigen-presenting capacity of
THP-1 cells, the CD8
+ immune response and TNF-a
production [49]. To sum up, EFhd2 is expressed across
species in many cell types of the innate and adaptive
immune system. It is tempting to speculate that EFhd2
is involved in Syk activation downstream of other
immune receptors than the BCR and plays a role in
antigen presentation.
Connection of EFhd2 to the cytoskeleton
Migration and phagocytotic activity of macrophages
require a dynamic cytoskeleton. For instance, the small
GTPase Cdc42 is required for cellular polarity, forma-
tion of filopodia and Fcg-receptor mediated phagocytosis
[50,51]. Rac is required for cell migration and Fcg-
receptor mediated phagocytosis [50,52,53] and Rho is
required to retract the trailing edge of migrating cells
and for uptake of apoptotic cell fragments [50,54].
EFhd2 is associated with the cytoskeleton in the human
mast cell line HMC-1 and in NK-like cells [29,35]. More
specifically, EFhd2 is associated in a caspase-9-contain-
ing complex with the cytoskeletal protein ezrin [55]. In
t h eb r a i no fam o u s em o d e l( J N P L 3m o u s e )[ 5 6 ]f o r
neurodegeneration (frontotemporal dementia and par-
kinsonism linked to chromosome 17; FTDP-17), where
neurodegeneration and neuroinflammation are induced
through transgenic expression of a mutated human tau
gene (htau P301L), EFhd2 was identified in a complex
with the transgenic human tau protein [15]. In addition,
endogenous EFhd2 and tau associate in brain lysates of
humans with Alzheimer’s disease and FTDP-17 [15].
Finally, EFhd2 becomes dephosphorylated after epider-
mal growth factor (EGF) stimulation of HeLa cells with
the same kinetics as the actin binding protein gelsolin
[42]. Taken together, these data demonstrate that EFhd2
is associated with the cytoskeleton but the exact connec-
tion is unknown at present. However, the related AIF-1
is associated with the cytoskeleton as well and involved
in macrophage survival, migration and activation [57].
Specifically, it augments macrophage phagocytotic activ-
ity [58]. Calcium binding to AIF-1 by means of its func-
tional EF-hand is required for its ability to activate Rac
Dütting et al. Cell Communication and Signaling 2011, 9:2
http://www.biosignaling.com/content/9/1/2
Page 5 of 14or G-CSF expression in vascular smooth muscle cells
[59]. Similarly, EFhd2 also binds calcium directly [15]
which may lead to interactions with cytoskeletal regula-
tors to modulate functions of innate immune cells, such
as cell migration, phagocytosis and antigen presentation.
In fact, in the human mast cell line HMC-1 EFhd2
co-localizes with, and modulates F-actin [29].
Involvement of EFhd2 in NF-B regulation
In the human mast cell line HMC-1 (which lacks the
Fcε receptor) EFhd2 augments expression of pro-
inflammatory cytokines after phorbol myristyl acetate
(PMA)/ionomycin stimulation. Similarly, AIF-1 augments
expression of IL-6, IL-12 but also IL-10 after lipopoly-
saccharide (LPS) stimulation of macrophages [60].
Therefore, in macrophages and a mast cell line, perhaps
also in primary mast cells (where EFhd2 is expressed;
our unpublished data), EFhd2 appears to reveal pro-
inflammatory activities, perhaps through positive regula-
tion of the protein kinase C b/nuclear factor B (PKCb/
NF-B) signaling pathway [29]. The PKCb pathway is
also activated by the BCR downstream of PLCg2/Ca
2+
signaling and induces eventually NF-B activation
through the Carma1/Bcl10/MALT1 complex [61]. A
positive regulation of PKCb/NF-B through EFhd2
would therefore be expected as we showed recently that
EFhd2 augments BCR-induced Syk/PLCg2/Ca
2+ signal-
ing in the murine B cell line WEHI231 [14]. Unexpect-
edly, however, we showed already that EFhd2 rather
blocks expression of the anti-apoptotic NF-Bt a r g e t
gene bclxL [31]. An explanation could be that EFhd2
binds calcium directly [15] and is therefore part of a
negative feedback loop preventing NF-B activation
after BCR stimulation (Figure 3). Apoptosis in lympho-
cytes is effectively controlled by the transcription factor
NF-B [62]. In the murine B cell line WEHI231 that is
susceptible to BCR-induced apoptosis, EFhd2 positively
regulates spontaneous and BCR-induced apoptosis [31].
Silencing of EFhd2 by shRNA augments survival of
WEHI231 cells spontaneously and in response to BCR
stimulation. In contrast, G1 cell cycle arrest and p27Kip
up-regulation are still induced by BCR ligation in the
absence of EFhd2 [31]. To conclude, EFhd2 regulates
specifically apoptosis, but not cell cycle arrest in
WEHI231 cells. We propose that this is due to suppres-
sion of the NF-B pathway in this cell line. The pro-
apoptotic activity of EFhd2 was suppressed by three sti-
muli that activate NF-B( C D 4 0l i g a t i o n ,L P S ,a n dB
cell activating factor of the TNF family [BAFF]) [31].
These data seem to oppose data from the mast cell line
HMC-1 where EFhd2 augmented up-regulation of NF-
kB target genes after PMA/ionomycin stimulation [29],
many of which are anti-apoptotic. However, PMA/iono-
mycin stimulation as used in HMC1 cells [29] and BCR
ligation in WEHI231 cells are different stimuli. EFhd2
may enhance BCR-mediated cell death in WEHI231
cells through inhibition of the NF-Bp a t h w a yb u t ,
through an unknown molecular switch, enhance like-
wise the NF-B activating and anti-apoptotic activities
of CD40, LPS, and BAFF in combination with BCR
stimulation.
Engagement of EFhd2 in autoimmune disorders
Regulation of the NF-B pathway by EFhd2, be it posi-
tive or negative, together with its expression in innate
and adaptive immune cells and its effects on cytokine
production [29] argue for involvement of EFhd2 in nor-
mal and pathological immune activation. In fact, PBMC
of rheumatoid arthritis (RA) patients express less EFhd2
protein than PBMC of healthy patients [36]. Moreover,
there is a protease-mediated cleavage of EFhd2 in RA
patients [37]. Expression of pro-apoptotic factors in
both B and T cells is important to establish tolerance of
t h ea d a p t i v ei m m u n es y s t e m[ 6 3 ] .I fE F h d 2w a sd o w n -
regulated in B cells their survival might be prolonged.
This might contribute to the persistence of autoimmune
diseases such as RA and SLE [64]. Interestingly, the
EFhd2-related AIF-1 is involved in RA as well [57].
Moreover, the murine efhd2 gene is Iocated rather cen-
trally in an SLE susceptibility region (LMB-1, close to
D4Mit33) on chromosome 4 [17], thereby, representing
a putative genetic determinant of SLE. Memory B cells
become persistently re-activated in RA and SLE [65]. In
memory B cells as well as in CD4
+ and CD8
+ memory
T cells, efhd2 expression is part of an evolutionary con-
served transcriptional signature [32]. Whether efhd2
expression in immune memory cells is important for
their activation, to keep them silent, or to help them
patrolling through secondary lymphatic organs is
unknown at present but certainly deserves further inves-
tigation with respect to autoimmune diseases.
EFhd2 and neuropathological disorders
Neurodegenerative disorders associated with tau,
so-called tauopathies, are characterized by successive
deposition of protein aggregates consisting of hyperpho-
sphorylated tau [66,67]. In Parkinson’s patients, tau and
nitrated a-synuclein induce formation of so-called Lewy
bodies that are characteristic for Parkinson’sd i s e a s e
[68]. Tau aggregates and Lewy bodies cause synapse loss
and neuronal cell death. In addition, neurodegenerative
diseases reveal an inflammatory component represented
mainly by microglial activation [69]. There are several
lines of evidence that EFhd2 is involved in normal and
pathological brain function: First, in microglia cells,
EFhd2 becomes up-regulated and secreted in response
to stimulation with nitrated a-synuclein [39]. Very
interestingly, the related AIF-1 (Iba1) is a microglial
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mouse model (JNPL3 mouse) [56] where neurodegen-
eration and neuroinflammation are induced through
transgenic expression of a mutated human tau (htau
P301L) contains complexes of the transgenic human tau
protein and endogenous EFhd2 [15] (Figure 3). In addi-
tion, endogenous EFhd2 and tau associate in brain
lysates of humans with Alzheimer’s disease and FTDP-
17 [15]. Third, EFhd2 is present in membrane rafts of
mouse spinal cord, but only when mice over-express a
mutant, toxic gain of function form of superoxide
dismutase 1 (SOD1), namely the G93A mutant [71]
(Figure 3). This mutant is responsible for familial
amyotrophic lateral sclerosis, a chronic, progressive
neuromuscular disorder [72]. Fourth, EFhd2 is down-
regulated in Nogo-A knockout mice that reveal
increased neurite growth and an increased regeneration
potential when compared to wildtype control mice
[73]. Fifth, in the frontal cortex of schizophrenic
patients EFhd2 becomes up-regulated together with
microtubule associated proteins [24]. Whether all these
data represent a causative connection of EFhd2 with
neurodegenerative diseases on the one hand, with neu-
ronal regeneration on the other hand or are merely
secondary effects is not known at present. Given the
increasing incidence of neurodegenerative diseases, it
would potentially be important to examine EFhd2
expression and function in human inflammatory
Figure 3 Involvement of EFhd2 in membrane and cytoskeleton associated pathways. EFhd2 can associate with detergent resistant
membranes (DRM) thought to represent membrane rafts in some B cell lines. Membrane raft association of EFhd2 was also detected in nervous
tissue of mice that express a gain of function mutant (G93A) of SOD1. EFhd2 has been shown to exhibit NF-B-activating as well as NF-B-
inactivating functions in different cell types. Through regulation of NF-B, EFhd2 may regulate survival or apoptosis of diverse cell types. The
interactions of EFhd2 with the SH3 domains of Lyn, PLCg and Fgr are based on GST-Pull down experiments using recombinant SH3 domains
(see Ref. 14). The interactions of Fgr and Lyn SH3 domains with EFhd2 depend on phosphorylation and the SH3 domain of Fgr binds to the
predicted proline-rich (PR) SH3 domain binding region of EFhd2. Three phosphorylation sites of EFhd2 are known: S74, S76 and Y83. S74 is a
cyclin dependent kinase 1 (Cdk1) site. The ability of EFhd2 to bind calcium may regulate its function and its association with the cytoskeleton.
EFhd2 also interacts with hyperphosphorylated Tau in a FTDP17 mouse model as well as in FTDP17 and Alzheimer’s patients.
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in murine mouse models for these diseases.
Involvement of EFhd2 in membrane associated pathways
T h ep l a s m am e m b r a n ec o n t a i n sc h o l e s t e r o la n ds p h i n -
golipid-enriched microdomains (detergent resistant
membranes, DRM) that are thought to function in many
membrane-associated processes, such as immune recep-
tor signaling [74]. In addition, microdomains control
vesicular trafficking, signaling of various receptors other
than immune receptors, and cytoskeletal rearrangement
[75]. Microdomains and their associated scaffold pro-
teins have also been implicated in the pathogenesis of
several neurological diseases, such as Parkinson’sa n d
Alzheimer’s disease [76] (see paragraph above). EFhd2
was discovered by us through a proteomic analysis of
DRM of B cell lines that differ in their apoptotic
response to BCR stimulation [30]. We found that EFhd2
associates with DRM in cell lines which undergo
apoptosis after BCR stimulation [30] and indeed, as
mentioned above, EFhd2 augments BCR signaling and
BCR-induced apoptosis in one of these cell lines exam-
ined [14,31]. It was tempting to speculate that the DRM
association of EFhd2 controls these effects. More
recently we could actually show that the BCR-induced
increase in intracellular calcium concentration is depen-
dent on the DRM association of EFhd2 in WEHI231
cells [14]. However, EFhd2 was not associated with
DRM in the murine B cell line CH27 [30]. We conclude
that membrane raft association of EFhd2 is not constitu-
tive but regulated, presumably in a cell type-specific
manner. Hence, DRM association of EFhd2, and thereby
its function, may be regulated by a specific pathway
active in some cell types. There exist two lines of evi-
dence for this hypothesis:
First, the predicted SH3-binding region (aa 70-78) of
EFhd2, targeting EFhd2 to DRM, binds specifically to
the SH3 domain of the tyrosine kinase Fgr [14] (Figure
3). In B cells, Fgr is only expressed late in B cell devel-
opment [77] and there is only one study to our knowl-
edge that examined DRM association of Fgr [78]. This
study revealed that, in contrast to other Src family
kinases, Fgr is not associated with DRM, at least in
RAW264.7 cells [78]. Hence, once Fgr is expressed, it
could keep EFhd2 out of DRM. The SH3 domain of Lyn
that also binds to EFhd2 [14] could conversely maintain
DRM association of EFhd2 (Figure 3). While Lyn is
expressed throughout B cell development, Fgr is
expressed in mature primary B cells, mantle zone B cells
and during myelomonocytic differentiation, but not in
immature primary B cells [77,79], which might regulate
the subcellular localisation and the function of EFhd2 in
mature B cells. Interestingly, we observed a phosphory-
lation-dependent interaction of EFhd2 with Lyn and Fgr
[14]. Phosphorylation of murine and human EFhd2 at
serine residues 74 and 76 [80-83] and, in brain lysates,
of tyrosine 83 [38], have been described. Lipopolysac-
charide stimulation of macrophages does not alter the
phosphorylation of EFhd2 significantly [83]. In our
hands, EFhd2 was not phosphorylated on tyrosine before
or after BCR engagement as judged by western blotting
with the anti-pY mAb PY99 (D.M. et al., unpublished
data). In conclusion, phosphorylation of either serine 74 or
76, or both, or other sites would appear to mediate bind-
ing of EFhd2 to the SH3 domains of Fgr and Lyn. Interest-
i n g l y ,S 7 4a n dS 7 6o fE F h d 2a r eC d k 1( c y c l i nd e p e n d e n t
kinase 1) phosphorylation sites [80]. Cdk1 is expressed
and active during the G2/S phase of the cell cycle [84],
that is, in activated B cells, which are present for instance
in germinal centers [85]. Hence, EFhd2 could be modified
by phosphorylation to modulate BCR signals in cycling B
cells where the BCR induces G1 arrest and apoptosis [86],
both of which are enhanced by EFhd2 [31].
Second, EFhd2 is present in DRM of mouse spinal
cord, but only when mice over-express a mutant, toxic
gain of function form of superoxide dismutase 1
(SOD1), namely the G93A mutant [71]. This mutant is
responsible for familial amyotrophic lateral sclerosis, a
chronic, progressive neuromuscular disorder [72]. Inter-
actions of DRM with the cytoskeleton have been well
documented [75]. Interestingly, the G93A mutant of
SOD1 also induces DRM association of cytoskeletal pro-
teins, such as ezrin, clathrin, actin depolymerising factor
and Arp2/3 [71] (Figure 3). In accordance, EFhd2 has
been identified in a complex with ezrin [55]. Under cer-
tain yet to be defined circumstances, EFhd2 may target
ezrin, clathrin and others to DRM or become targeted
to DRM by cytoskeletal proteins. De-phosphorylation of
ezrin after BCR-triggering is important to induce DRM
association of the BCR at late time points (more than 15
min) [87]. We have also shown that, at least in the mur-
ine B cell line WEHI231, EFhd2 induces constitutive
association of the BCR, PLCg2 and Syk with DRMs [14].
Taken together, EFhd2 may function as a DRM - cytos-
keleton integrator through as yet not well characterized
protein-protein or protein-lipid interactions.
Proposed function(s) of EFhd2
As detailed above, EFhd2 is a cytoskeleton associated
adaptor protein involved in immune and normal as well
as pathological neuronal functions, and perhaps in cal-
cium homeostasis. This may be important for immune
cell signaling and signaling pathways within or arising
from neurological synapses. In accordance, EFhd2 is
regulated under inflammatory conditions in immune
and brain cells. Hence, we propose that EFhd2 is a mod-
ulator of immune and brain cell function under both
basal and inflammatory conditions.
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Expression of EFhd1
EFhd1 was first described as mitocalcin. It was identified
in an attempt to isolate genes involved in neuronal dif-
ferentiation in 2Y-3t cells, a neuronal progenitor cell
line established from an adult p53-deficient mouse cere-
bellum [88]. In 2Y-3t cells EFhd1 is up-regulated during
differentiation. In vivo, EFhd1 is expressed both in cere-
bellum and cerebrum [16,88]. Its expression increases
postnatally. In adult mice, neurons of cerebellum, cere-
brum and hippocampus (cornu ammonis and dentate
gyrus) reveal efhd1 mRNA, but only low amounts are
present in the white matter of cerebellum and cerebrum
[88]. The Purkinje-layer, the internal granule cell layer
and the molecular layer, however, do express EFhd1. In
addition, spermatocytes, interstitial cells of adult testis
and granulosa cells of the cumulus oophorus (cumulus
cells) as well as mural granulosa cells in adult ovary
exhibit EFhd1 expression [16,88]. EFhd1 is also
expressed in IGF-II-deficient murine C2 myoblasts [89].
There, efhd1 mRNA ceases in the absence of the tran-
scriptional co-activator p300 [89]. Healthy human renal
tissue expresses efhd1 mRNA [90] and in murine kidney
the collecting ducts, but not the glomeruli, reveal EFhd1
[16,88]. Interestingly, EFhd1 expression is repressed in
renal cell carcinoma (RCC) [90]. In contrast, EFhd1 is
present in tumour tissues from patients with stage III
and IV melanoma and increased expression of EFhd1 is
significantly associated with shorter patient survival
times [91]. Whereas EFhd1 has been proposed to exhibit
tumour suppressing functions in RCC [90], growth pro-
moting functions may be associated with other tumours.
Concomitantly, uterine fibroids reveal less efhd1 mRNA
than normal myometrium [92]. Under more physiologi-
cal conditions EFhd1 becomes up-regulated at term
when compared with midgestation [93]. In contrast,
human endometrial cells down-regulate EFhd1 after tro-
phoblast co-culture [94].
Function of EFhd1 in normal and malignant tissue
Using an SDS-gel shift assay EFhd1 has been shown to
bind calcium [88]. It associates with the mitochondrial
inner membrane [16] and over-expression results in
neurite extension of 2Y-3t cells. Conversely, down-regula-
tion of EFhd1 through siRNA suppresses neurite out-
growth and promotes cell death [16]. Based on these
findings Tominaga and co-workers suggested that EFhd1
is involved in neuronal differentiation and operates
through control of mitochondrial function [16]. Whether
this proposed function correlates with the calcium bind-
ing activity of EFhd1 is not known at present. Mitochon-
dria, however, are important reservoirs of calcium.
Interestingly, ectopic expression of manganese superoxide
dismutase 2 (SOD2), a mitochondrial enzyme that
inactivates superoxide to protect cells from oxidative
damage, induces down-regulation of EFhd1 in a pancrea-
tic carcinoma cell line. Conversely, reduction of SOD2
abundance causes increased EFhd1 expression in a
human pancreatic carcinoma cell line (MIA-PaCa2) [95].
At first glance it is therefore puzzling that reduction of
SOD2 increases neuronal cell death by activating cell
death pathways [96,97]. An explanation could be that up-
regulation of EFhd1 through reduced SOD2 expression
[95] may be part of an anti-apoptotic mechanism antago-
nizing oxidative stress in neuronal cells (Figure 4). An
example of a small calcium binding protein antagonizing
oxidative stress is calmodulin: After calcium binding, cal-
modulin interacts with antioxidant enzymes involved in
ROS homeostasis [1]. A similar mechanism may apply to
EFhd1 in a tissue-specific manner.
Sustained activation of the autocrine IGF-II pathway is
critical for myoblast viability and differentiation [98].
Gene expression profiling of IGF-II-deficient myoblasts
that undergo apoptosis when incubated in differentia-
tion-promoting medium revealed new mediators of
CBP/p300 promoted survival. Myoblasts expressing
CBP/p300 showed a 17-fold up-regulation of EFhd1
[89]. This indicates that EFhd1 might be a factor causing
CBP/p300 mediated survival in muscle cells. Interestingly,
together with PCAF, the transcriptional co-activator
CBP/p300 is a key player in neuronal outgrowth by acety-
lating histones and p53 [99] and exhibits neuroprotective
functions [100]. It is tempting to speculate that CBP/p300
up-regulates EFhd1 also in neuronal tissue to promote
neuronal survival.
As readily mentioned above, EFhd1 expression has
also been described in kidney. This is repressed in renal
cell carcinoma (RCC) when compared to healthy tissue
[90]. The same holds true for the transcription factor
HNF4a (hepatocyte nuclear factor 4a). This suggests
that HNF4a exhibits tumour suppressing functions
[101]. Interestingly, HNF4a increases expression of
EFhd1, revealing that efhd1 is a target gene of HNF4a
[90,102]. Very recently, an independent microarray ana-
lysis confirmed this initial finding [103]. Ectopic
HNF4a- e x p r e s s i o nr e d u c e sp r o l i f e r a t i o ni nH E K 2 9 3
c e l l s( ah u m a ne m b r y o n i ck i d n e yc e l ll i n e )a n dt h e r e -
fore, the authors postulate a possible tumour suppressor
activity of HNF4a [102]. However, inducible EFhd1
expression in HEK293 cells revealed that EFhd1 rather
augments proliferation slightly [102]. Therefore, efhd1 is
aH N F 4 a target gene that appears to oppose the prolif-
eration suppressing effect of HNF4a in HEK293 cells.
Additionally, HNF4a up-regulates hepatocyte iNOS
(inducible nitric oxide synthetase) in response to the
inflammatory redox state [104,105]. iNOS exhibits anti-
oxidant and anti-apoptotic functions. Hence, it is likely
that HNF4a senses the inflammatory redox state in
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chondrial localization of EFhd1, its ability to promote
differentiation of 2Y-3t cells and its converse regulation
by the redox factors SOD2 and HNF4a suggest that
E F h d 1i sp a r to far e d o x - s e n s itive network controlling
cell survival and/or differentiation (Figure 4). Whether
EFhd1 is actually a survival promoting or tumour sup-
pressing factor may depend on the cell type and envir-
onmental context. For example, under pathological
conditions, such as hypoxia and ischemia/reperfusion
injury, mitochondrial dysfunction results in ROS
increase. Normal tissue responds to this challenge with
calcium overload, followed by mitochondrial depolariza-
tion, cytochrome c release and apoptosis [1]. Tumours,
however, have developed mechanisms to survive hypoxia
and ROS increase. One of these factors might be EFhd1.
A combined genome-wide ChIP sequencing analysis
with gain- and loss-of-function transcriptome analyses
in early-stage B cells identified promoters of genes with
Ebf1 (early B cell factor-1) binding sites. IL-7 cultured
pro-B cells, in which Ebf1 was conditionally inactivated,
express less EFhd1 [106], suggesting that efhd1 is a tar-
get gene of Ebf1. Hnf4a was also described as direct tar-
get of the transcription factor Ebf1 in common
lymphoid progenitors [107] and common lymphoid pro-
genitors are subject to oxidative stress [108]. Thus, Ebf1
may up-regulate EFhd1 through HNF4a.T h e s ed a t a
point to a function of EFhd1 during early B cell devel-
opment, an issue we are currently addressing. In
contrast to transcriptional activators of efhd1, Suz12 is a
transcriptional repressor as part of the transcriptional
repressor complex PRC2 (polycomb repressor complex)
in murine terato-carcinoma cells [109]. These complexes
are normally highly abundant in embryonic tissues and
are essential for development. In adult tissues, expres-
sion of Suz12 is very low [110,111] but it is very abun-
dant in a variety of human tumours. PRC2 catalyzes
trimethylation (me3) of histone 3 lysine 27 (H3K27),
thereby, mediating transcriptional repression. Conse-
quently, targeting of the efhd1 promoter by Suz12
should lead to decreased or no expression of EFhd1.
Conclusions
Calcium binding proteins of the EF-hand are involved in
all aspects of cellular functions. EFhd2 and EFhd1 are
two related EF-hand containing adaptor proteins with a
similar predicted overall structure. Both proteins bind
calcium, but they differ in their sites of expression as well
as in their proposed function in different cell types.
EFhd2 is a cytoskeleton associated adaptor protein
involved in immune and brain cell function and acts
likely in response to changes in calcium homeostasis.
EFhd1 is involved in neuronal differentiation and operates
through control of mitochondrial function. Furthermore
EFhd1 could be part of a redox-sensitive network con-
trolling cell survival and/or differentiation depending on
the cell type and environmental context. Whereas EFhd1
and EFhd2 are almost identical in the C-terminal part
Figure 4 Involvement of EFhd1 in survival and redox regulated pathways. EFhd1 has been described as a survival factor for neuronal cells
and been proposed to mediate muscle cell survival. In response to oxidative stress that can be blocked by superoxide dismutase 2 (SOD2),
HNF-4a (hepatocyte nuclear factor 4a) becomes activated. EFhd1 is a direct target of HNF-4a and its expression is repressed by SOD2. Thus,
EFhd1 may be involved in a protective cellular response against oxidative stress and, thereby, exhibit anti-apoptotic functions in diverse cell
types. Early B cell factor 1 (Ebf1) positively regulates EFhd1 expression in early B cells whereas Suz12 as part of the polycomb repressor complex
2 (PRC2) is a negative regulator of EFhd1 expression.
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non-homologous moiety between aa 20-80 in front of the
EF-hands shows the most differences between EFhd2 and
EFhd1, as well as between orthologues of EFhd2 and
EFhd1. As a result, EFhd2 and EFhd1 may bind distinct
proteins redundantly while others uniquely, thereby,
transmitting alterations in the intracellular calcium con-
centration into different signaling outcomes. Hence it
appears comprehensible that expression of EFhd2 and
EFhd1 is tightly controlled and regulated to ensure effi-
cient function of the respective cell type. Besides the
compelling necessity to clarify the detailed functions and
signaling pathways of EFhd2 and EFhd1 in different cellu-
lar contexts, future work has to address possible redun-
dancies of EFhd2 and EFhd1. Therefore, it is reasonable
to generate and cross EFhd2 knockout and transgenic
mice with the respective Efhd1 mice and analyze the
impact in function and development, especially with
regard to the immune and nervous system, as well as the
progression of tumours.
Additional material
Additional file 1: Table S1 Murine EFhd1 and EFhd2 genes,
transcripts and proteins. This table displays the nomenclature of
murine EFhd1 and EFhd2 proteins and transcripts as well as gene locus
information.
Additional file 2: Figure S1 Aligment of EFhd1 Orthologues.
Aligment of human (Q9BUP0), murine (Q9D41J), rat (D4A9T5), bovine
(Q17QM6) and frog (Q6GP23) EFhd1 using ClustalW2 (http://www.ebi.ac.
uk/clustalw). Amino acid (aa) positions are marked on the right. “*”,
identical aa, “:”, conserved aa, “.” semi conserved aa.
Additional file 3: Figure S2 Sequence homology of murine AIF-1
with EFhd1 and EFhd2. A standard blast search with murine AIF-1
(AAC82481.1) was performed against all murine non-redundant GenBank
CDS translations + PDB + SwissProt + PIR + PRF excluding
environmental samples from WGS projects. Homologies between the first
EF-hand of AIF-1 and the EF-hands of EFhd1/2 are only shown for the
second EF-hands of EFhd1 and EFhd2.
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